Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Financing Activities data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 73.04% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $249.7 million, a 46.87% increase from a year earlier, with the FY2025 full-year figure at $256.0 million, down 65.18% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.3 million, down from $9.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for MDGL reached as high as $573.7 million in Q1 2024 and fell as low as $1.7 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $126.8 million across 5 years, with a median of $42.9 million in 2023.
• On a YoY basis, Cash from Financing Activities climbed as much as 3071.36% in 2025 and fell as far as 98.7% in 2025.
• Year by year, Cash from Financing Activities stood at $264.3 million in 2022, then soared by 81.55% to $479.9 million in 2023, then slumped by 95.88% to $19.8 million in 2024, then tumbled by 54.7% to $9.0 million in 2025, then slumped by 74.0% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.3 million in Q1 2026, $9.0 million in Q4 2025, and $236.6 million in Q3 2025.